New insider activity at Alzamend Neuro ( (ALZN) ) has taken place on July 29, 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Director Milton C III Ault recently sold 44,843 shares of Alzamend Neuro stock, amounting to a total transaction value of $127,850.
Recent Updates on ALZN stock
In the last 24 hours, Alzamend Neuro’s stock experienced a significant surge, rising by 145% following an update on their study. The company has reported a strengthened financial position, with net cash provided by financing activities amounting to $10.4 million for the fiscal year ending April 30, 2025. This improvement is attributed to strategic fiscal management and effective capital allocation. Alzamend Neuro also announced the successful completion of a $5 million private placement, which will fund five Phase II clinical trials of their AL001 “Lithium in Brain” studies in collaboration with Massachusetts General Hospital and Harvard Medical School. The dosing of the first patient in the Phase II study of AL001 further contributed to positive market sentiment. These developments have bolstered investor confidence, reflected in the sharp increase in stock price.
More about Alzamend Neuro
YTD Price Performance: -73.47%
Average Trading Volume: 1,706,321
Technical Sentiment Signal: Sell
Current Market Cap: $8.02M